The HPV vaccine does help prevent throat cancer, and in 2020 the FDA formally expanded its approved uses to include prevention of HPV-related oropharyngeal cancers (cancers of the tonsils, base of the tongue, and back of the throat). This matters because HPV causes roughly 70% of oropharyngeal cancers in the United States, making it the dominant driver of a cancer that now affects more than 22,000 Americans each year.
How HPV Causes Throat Cancer
HPV doesn’t cause throat cancer overnight. The virus, particularly HPV type 16, infects cells in the lining of the throat and produces two proteins that essentially disable your body’s built-in cancer defenses. One protein destroys p53, a molecule that normally stops damaged cells from multiplying. The other knocks out Rb, which acts as a brake on cell division. With both of those safety switches turned off, infected cells can divide uncontrollably, accumulate genetic errors, and eventually become cancerous.
This process typically unfolds over years or even decades. Most people who contract oral HPV clear the infection on their own. But in a fraction of cases, the virus persists, integrates into the cell’s DNA, and slowly pushes the tissue toward malignancy. That long timeline is part of why oropharyngeal cancer diagnoses are climbing now, even as vaccination rates among younger people rise: many of today’s patients were infected long before the vaccine existed.
How Well the Vaccine Works Against Oral HPV
The vaccine was originally developed and studied for cervical cancer prevention, but the same HPV types that cause cervical cancer also cause throat cancer. About 85% of HPV-related head and neck cancers are linked to HPV types 16 and 18, both of which the vaccine targets.
Data presented at the American Society of Clinical Oncology Annual Meeting found that young adults who received at least one dose of the HPV vaccine had an 88% reduction in detectable HPV in their oral cavities compared to unvaccinated peers. A separate prospective study in Costa Rica found a 93% reduction in oral HPV prevalence among vaccinated women. These are reductions in the oral infections that precede cancer, not direct measurements of cancer prevention, since it takes decades for cancer to develop. But eliminating the infection that starts the process is the most reliable way to prevent the cancer it causes.
Vaccination Timing Makes a Big Difference
The vaccine works best when given before any exposure to HPV, which in practice means before sexual activity begins. Data from the National Cancer Institute illustrate this clearly: among women eligible for vaccination, those who were never vaccinated had an HPV 16/18 prevalence of about 6%. Vaccination after sexual debut cut that to 3%, a 41% reduction. But vaccination before sexual debut dropped prevalence to less than 1%, an 89% reduction from unvaccinated levels. That gap between “before” and “after” sexual debut represents an 82% difference in effectiveness.
This is why the CDC recommends routine HPV vaccination at age 11 or 12, though it can be given as early as 9. For those who missed that window, catch-up vaccination is recommended through age 26. Adults aged 27 through 45 can also receive the vaccine after discussing it with their healthcare provider, though the benefit is smaller because most people in that age range have already been exposed to HPV.
Why Throat Cancer Is Now a Bigger Concern Than Cervical Cancer
HPV-related oropharyngeal cancer has quietly overtaken cervical cancer as the most common HPV-caused cancer in the United States. CDC data from 2018 to 2022 show roughly 16,000 cases of throat cancer attributable to HPV each year, compared to about 11,100 cases of HPV-caused cervical cancer. The gap exists largely because cervical cancer screening (Pap smears and HPV tests) catches precancerous changes early, while no equivalent screening test exists for the throat.
Men bear the brunt of this trend. Each year, more than 18,700 men are diagnosed with oropharyngeal cancer compared to about 3,800 women, a ratio of more than four to one. Oropharyngeal cancer is now the most common HPV-associated cancer among men. Despite this, male HPV vaccination rates have historically lagged behind female rates, partly because the vaccine was initially marketed and recommended primarily for girls and young women.
How Long Protection Lasts
Ten-year follow-up studies show that immunity remains strong long after vaccination. Among women vaccinated between ages 15 and 25, more than 96% remained seropositive for HPV-16 antibodies and over 99% for HPV-18 antibodies a full decade later. Antibody levels stayed well above what the body produces after a natural infection: at least 5.3 times higher for HPV-16 and 3.1 times higher for HPV-18. Mathematical models based on these antibody trajectories predict protection will persist for 30 years or more across all age groups studied.
No booster dose is currently recommended. The three-dose series (or two-dose series for those who start before age 15) appears to provide durable protection that covers the critical years when new HPV infections are most likely.
What the Vaccine Cannot Do
The vaccine prevents new HPV infections. It does not treat existing infections or reverse precancerous changes already underway. If you were infected with HPV before vaccination, the vaccine won’t clear that particular infection, though it can still protect you against HPV types you haven’t yet encountered. About 30% of oropharyngeal cancers are not caused by HPV at all, so the vaccine would have no effect on those cases, which are more often linked to tobacco and alcohol use.
There is also no way to screen for early-stage HPV-related throat cancer the way a Pap smear screens for cervical cancer. This makes prevention through vaccination especially valuable. Symptoms of oropharyngeal cancer, such as a persistent sore throat, difficulty swallowing, ear pain on one side, or a lump in the neck, often don’t appear until the cancer is more advanced.